Pulmonary embolism in the critically ill

Chest

Volumn 132, Issue 1, 2007, Pages 313-324

  Carlbom, David J ^a   Davidson, Bruce L ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Anticoagulation; Bleeding; Critical care; Heparin induced thrombocytopenia; Intensive care; Pulmonary embolism

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTIDOTE; ARGATROBAN; BLOOD CLOTTING FACTOR 8 INHIBITOR; BRAIN NATRIURETIC PEPTIDE; DALTEPARIN; DESMOPRESSIN ACETATE; ENDOTHELIN; ENOXAPARIN; FIBRIN; FONDAPARINUX; HEPARIN; LEPIRUDIN; NITRIC OXIDE; PLASMIN; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RETEPLASE; SILDENAFIL; STREPTOKINASE; TENECTEPLASE; THROMBOPLASTIN; THROMBOXANE; TINZAPARIN; TROPONIN I; TROPONIN T; UNINDEXED DRUG; UROKINASE; VASODILATOR AGENT;

ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; CRITICAL ILLNESS; ECHOCARDIOGRAPHY; EMBOLECTOMY; FIBRINOLYTIC THERAPY; FLUID THERAPY; HEART LEFT VENTRICLE FUNCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; RESUSCITATION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT OUTCOME; VASODILATATION; VENA CAVA FILTER;

EID: 34447503966     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.06-1854     Document Type: Article

References (65)

1. Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002; 121:877-905
2. Kucher N, Goldhaber SZ. Management of massive pulmonary embolism. Circulation 2005; 112:e28-e32
3. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl):401S-428S
4. ten Wolde M, Sohne M, Quak E, et al. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med 2004; 164:1685-1689
5. Kucher N, Rossi E, De Rosa M, et al. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med 2005; 165:1777-1781
6. Reid JH, Murchison JT. Acute right ventricular dilatation: a new helical CT sign of massive pulmonary embolism. Clin Radiol 1998; 53:694-698
7. Sukbija R, Aronow WS, Yalamanchili K, et al. Association of right ventricular dilatation with bilateral pulmonary embolism, pulmonary embolism in a main pulmonary artery and lobar, segmental and subsegmental pulmonary embolism in 190 patients with acute pulmonary embolism. Cardiology 2005; 103:156-157
8. Schoepf UJ, Kucher N, Kipfmueller F, et al. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 2004; 110:3276-3280
9. van der Meer RW, Pattynama PM, van Strijen MJ, et al. Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism. Radiology 2005; 235:798-803
10. Kipfmueller F, Quiroz R, Goldhaber SZ, et al. Chest CT assessment following thrombolysis or surgical embolectomy for acute pulmonary embolism. Vasc Med 2005; 10:85-89
11. Pruszczyk P, Bochowicz A, Torbicki A, et al. Cardiac troponin T monitoring identifies high-risk group of normotensive patients with acute pulmonary embolism. Chest 2003; 123: 1947-1952
12. Mehta NJ, Jani K, Khan IA. Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J 2003; 145:821-825
13. Punukollu G, Khan IA, Gowda RM, et al. Cardiac troponin I release in acute pulmonary embolism in relation to the duration of symptoms. Int J Cardiol 2005; 99:207-211
14. Toth M, Vuorinen KH, Vuolteenaho O, et al. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. Am J Physiol 1994; 266:H1572-H1580
15. Sabatine MS, Morrow DA, de Lemos JA, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 2004; 44:1988-1995
16. Pruszczyk P, Kostrubiec M, Bochowicz A, et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 2003; 22:649-653
17. Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003; 107:2545-2547
18. Binder L, Pieske B, Olschewski M, et al. N-terminal probrain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 2005; 112:1573-1579
19. Scridon T, Scridon C, Skali H, et al. Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism. Am J Cardiol 2005; 96:303-305
20. Torbicki A. Thrombolysis in submassive pulmonary embolism. J Thromb Haemost 2004; 2:1476-1477
21. Mercat A, Diehl JL, Meyer G, et al. Hemodynamic effects of fluid loading in acute massive pulmonary embolism. Crit Care Med 1999; 27:540-544
22. Hirsch LJ, Rooney MW, Wat SS, et al. Norepinephrine and phenylephrine effects on right ventricular function in experimental canine pulmonary embolism. Chest 1991; 100:796-801
23. Capellier G, Jacques T, Balvay P, et al. Inhaled nitric oxide in patients with pulmonary embolism. Intensive Care Med 1997; 23:1089-1092
24. Szold O, Khoury W, Biderman P, et al. Inhaled nitric oxide improves pulmonary functions following massive pulmonary embolism: a report of four patients and review of the literature. Lung 2006; 184:1-5
25. Tanus-Santos JE, Theodorakis MJ. Is there a place for inhaled nitric oxide in the therapy of acute pulmonary embolism? Am J Respir Med 2002; 1:167-176
26. Griffiths MJ, Evans TW. Inhaled nitric oxide therapy in adults. N Engl J Med 2005; 353:2683-2695
27. Dias-Junior CA, Souza-Costa DC, Zerbini T, et al. The effect of sildenafil on pulmonary embolism-induced oxidative stress and pulmonary hypertension. Anesth Analg 2005; 101:115-120
28. Ganiere V, Feihl F, Tagan D. Dramatic beneficial effects of sildenafil in recurrent massive pulmonary embolism. Intensive Care Med 2006; 32:452-454
29. Goldhaber SZ. Thrombolysis for pulmonary embolism. N Engl J Med 2002; 347:1131-1132
30. Kucher N, Rossi E, De Rosa M, et al. Massive pulmonary embolism. Circulation 2006; 113:577-582
31. Verstraete M, Miller GA, Bounameaux H, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988; 77:353-360
32. Uflacker R. Interventional therapy for pulmonary embolism. J Vasc Interv Radiol 2001; 12:147-164
33. Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial; the European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol 1992; 19:239-245
34. Fatovich DM, Dobb GJ, Clugston RA. A pilot randomised trial of thrombolysis in cardiac arrest (the TICA trial). Resuscitation 2004; 61:309-313
35. Bottiger BW, Bode C, Kern S, et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. Lancet 2001; 357:1583-1585
36. Schmitz-Rode T, Janssens U, Schild HH, et al. Fragmentation of massive pulmonary embolism using a pigtail rotation catheter. Chest 1998; 114:1427-1436
37. Zeni PT Jr, Blank BG, Peeler DW. Use of rheolytic thrombectomy in treatment of acute massive pulmonary embolism. J Vasc Interv Radiol 2003; 14:1511-1515
38. Yalamanchili K, Fleisher AG, Lehrman SG, et al. Open pulmonary embolectomy for treatment of major pulmonary embolism. Ann Thorac Surg 2004; 77:819-823
39. Aklog L, Williams CS, Byrne JG, et al. Acute pulmonary embolectomy: a contemporary approach. Circulation 2002; 105:1416-1419
40. Leacche M, Unic D, Goldhaber SZ, et al. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg 2005; 129:1018-1023
41. Meneveau N, Seronde MF, Blonde MC, et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 2006; 129:1043-1050
42. Davidson B, Karmy-Jones R. When pulmonary embolism treatment isn't working. Chest 2006; 129:839-840
43. Wilson JE III, Pierce AK, Johnson RL Jr, et al. Hypoxemia in pulmonary embolism: a clinical study. J Clin Invest 1971; 50:481-491
44. Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med 2001; 135:98-107
45. Le Gal G, Righini M, Roy PM, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006; 144:165-171
46. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315:1109-1114
47. Hirsh J, van Aken WG, Gallus AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53:691-695
48. Dorffler-Melly J, de Jonge E, Pont AC, et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002; 359:849-850
49. Raschke RA, Gollihare B, Peirce JC. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Arch Intern Med 1996; 156:1645-1649
50. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56
51. Lubenow N, Eichler P, Lietz T, et al. Lepirudin in patients with heparin-induced thrombocytopenia: results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2/and HAT-3. J Thromb Haemost 2005; 3:2428-2436
52. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003; 108:2062-2065
53. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349:1695-1702
54. Wolzt M, Weltermann A, Nieszpaur-Los M, et al. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb Haemost 1995; 73:439-443
55. Mahdy AM, Webster NR. Perioperative systemic haemostatic-agents. Br J Anaesth 2004; 93:842-858
56. Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with severe bleeding. Br J Haematol 2001; 115: 998-1001
57. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352:777-785
58. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2:1700-1708
59. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106:2550-2554
60. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163:2518-2524
61. Warkentin TE. Should vitamin K be administered when HIT is diagnosed after administration of coumarin? J Thromb Haemost 2006; 4:894-896
62. White RH, Zhou H, Kim J, Romano PS. A population-based studv of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. Arch Intern Med 2000; 160:2033-2041
63. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis: Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998; 338:409-415
64. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized studv. Circulation 2005; 112:416-422
65. Mismetti P, Rivron-Guillot K, Quenet S, et al. A prospective long-term study of 220 patients with a retrievable inferior vena cava filter for secondary prevention of venous thromboembolism. Chest 2007; 131:223-229